RESUMO
Objective:To evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection in the treatment of peripheral T-cell lymphoma (PTCL) in a real-world setting.Methods:This was a real-world ambispective cohort study (MOMENT study) (Chinese clinical trial registry number: ChiCTR2200062067). Clinical data were collected from 198 patients who received mitoxantrone hydrochloride liposome injection as monotherapy or combination therapy at 37 hospitals from January 2022 to January 2023, including 166 patients in the retrospective cohort and 32 patients in the prospective cohort; 10 patients in the treatment-na?ve group and 188 patients in the relapsed/refractory group. Clinical characteristics, efficacy and adverse events were summarized, and the overall survival (OS) and progression-free survival (PFS) were analyzed.Results:All 198 patients were treated with mitoxantrone hydrochloride liposome injection for a median of 3 cycles (range 1-7 cycles); 28 cases were treated with mitoxantrone hydrochloride liposome injection as monotherapy, and 170 cases were treated with the combination regimen. Among 188 relapsed/refractory patients, 45 cases (23.9%) were in complete remission (CR), 82 cases (43.6%) were in partial remission (PR), and 28 cases (14.9%) were in disease stabilization (SD), and 33 cases (17.6%) were in disease progression (PD), with an objective remission rate (ORR) of 67.6% (127/188). Among 10 treatment-na?ve patients, 4 cases (40.0%) were in CR, 5 cases (50.0%) were in PR, and 1 case (10.0%) was in PD, with an ORR of 90.0% (9/10). The median follow-up time was 2.9 months (95% CI 2.4-3.7 months), and the median PFS and OS of patients in relapsed/refractory and treatment-na?ve groups were not reached. In relapsed/refractory patients, the difference in ORR between patients with different number of treatment lines of mitoxantrone hydrochloride liposome injection [ORR of the second-line, the third-line and ≥the forth-line treatment was 74.4% (67/90), 73.9% (34/46) and 50.0% (26/52)] was statistically significant ( P = 0.008). Of the 198 PTCL patients, 182 cases (91.9%) experienced at least 1 time of treatment-related adverse events, and the incidence rate of ≥grade 3 adverse events was 66.7% (132/198), which was mainly characterized by hematologic adverse events. The ≥ grade 3 hematologic adverse events mainly included decreased lymphocyte count, decreased neutrophil count, decreased white blood cell count, and anemia; non-hematologic adverse events were mostly grade 1-2, mainly including pigmentation disorders and upper respiratory tract infection. Conclusions:The use of mitoxantrone hydrochloride liposome injection-containing regimen in the treatment of PTCL has definite efficacy and is well tolerated, and it is a new therapeutic option for PTCL patients.
RESUMO
The Bruton tyrosine kinase (BTK) inhibitor ibrtinib has excellent results in B-cell lymphoma. However, there are still unmet treatment needs in clinical practice. New BTK inhibitors are highly selective and specific, reducing off-target effects. The overall response rate (ORR) of acalabrutinib combination therapy is more than 90%, and high rates of peripheral blood and bone marrow minimal residual disease (MRD)-negative are obtained. Orelabrutinib is a new domestic BTK inhibitor, the results of a phase Ⅱ study showed that the ORR in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma is 88.5%, and in mantle cell lymphoma is 82.5%. Another new domestic BTK inhibitor zanubrutinib, international multi-center study showed that ORR is 95.9% in relapsed/refractory CLL, and in treatment-na?ve chronic lymphocytic leukemia with del (17p) is 92.2%. In addition, non-covalent BTK inhibitors are also emerging, which are expected to overcome the problem of resistance to BTK inhibitors.
RESUMO
Diffuse large B-cell lymphoma (DLBCL) is the most common malignant lymphoma subtype. Although the R-CHOP standard treatment regimen improved the overall survival of DLBCL patients, the 5-year overall survival rate of high-risk patients was still less than 50％. DLBCL is always a hot spot for research and attention. For example, the combination of new drugs, immune-targeted therapy with chimeric antigen receptor T cells or antibody therapy, how to reduce the long-term adverse and the search for new prognostic biomarkers and typing systems. The recent progress of DLBCL reported in the 60th American Society of Hematology Annual Meeting is briefly introduced in this paper.
RESUMO
The 23rd Congress of the European Hematology Association (EHA) was held in Stockholm, Sweden from June 14-17, 2018. The latest analysis of three chimeric antigen receptor T-cell treatments for diffuse large B-cell lymphoma and clinical data from a number of immunotargeting drugs were presented at this congress, all showing encouraging results. The recent progress of aggressive B-cell non-Hodgkin lymphoma is briefly introduced in this paper.
RESUMO
Follicular lymphoma (FL) deriving from the germinal center B-cell, is the most common indolent B-cell non-Hodgkin''s lymphoma (NHL) and an incurable disease. FL was reported as the most attractive subtype of NHL at the 59th American Society of Hematology Annual Meeting. The current focus includes maintenance treatment after induction therapy, new drugs combined induction therapy and maintenance therapy, chemotherapy-free for FL and the investigation of new prognostic biology markers.
RESUMO
The 14th International Conference on Malignant Lymphoma (ICML) was held in Lugano, Switzerland from June 14, 2017 to June 17, 2017. More than 3500 lymphoma experts and scholars attended this unprecedented conference. In particular, the Joint Forum on Union for China Lymphoma Investigators (UCLI)-ICML jointly organised by UCLI and ICML had greatly improved Chinese academic status in the field of lymphoma worldwide. Chinese experience on the treatment of T-cell lymphoma was exchanged during the conference. This paper reviews the recent progress in treatment of T-cell lymphoma in the meeting.
RESUMO
In recent years, immunotherapy has become an indispensable part in treatment of cancer, and the immune checkpoint inhibitors are the focus of attention. In the 58th American Society of Hematology (ASH) Annual Meeting, the application of immune checkpoint inhibitors in hematologic malignancies had been widely concerned. The recent progress of immune checkpoint inhibitors in hematologic malignancies in this annual meeting will be briefly introduced.
RESUMO
The treatments of multiple myeloma (MM) have been made remarkable progress in recent years,and especially in 2015,FDA approved a number of new drugs for treatment of relapsed and refractory MM.At the 21th European Hematology Association Annual Meeting,the issue of MM has received a lot of attention.The recent progress of MM in this conference will be briefly introduced in this review.
RESUMO
In recent years, there has been significant progress in the treatment of malignant lymphoma, new drugs and new treatment strategies continue to emerge, such as chimeric antigen receptor (CAR) T cells immunotherapy. The issue of malignant lymphoma has received a lot of attention. The recent progress of malignant lymphoma reported in the 57th American Society of Hematology annual meeting were briefly introduced in this article.
RESUMO
<p><b>OBJECTIVE</b>To evaluate the early hematologic, cytogenetic and molecular responses in newly diagnosed patients with chronic myelogenous leukemia in chronic phase（CML-CP）and initially treated with a generic imatinib（Xinwei）, manufactured by Jiansu Hansoh Pharmaceutical Group Co., Ltd.</p><p><b>METHODS</b>107 newly diagnosed patients of CML-CP, whose ages were above 18- year- old and who had never received any tyrosine kinase inhibitor（TKI）were treated with Xinwei 400 mg QD. The hematologic, cytogenetic and molecular responses were assessed at 3- and 6-month, and adverse effects were evaluated throughout the study.</p><p><b>RESULTS</b>107 patients were treated with Xinwei for at least 3 months, 54 of them were treated for 6 months or more. At 3- month, the complete hematologic responses（CHR）rate were 98.1%（105/107）; 47/57（82.5%） patients achieved major cytogenetic response（MCyR）, and 20/57 （35.1%） patients complete cytogenetic response（CCyR）; BCR- ABLIS was ≤10% in 77/106 patients （72.6%）, 11 of them（10.4%）achieved major molecular response（MMR, BCR-ABLIS was ≤0.1%）. At 6-month, the CHR rate was 100%（54/54）; 28/39 patients（71.8%）achieved CCyR; BCR-ABLIS was ≤1% in 37/54 patients （68.5% ）, 18 of them （33.3% ） achieved MMR. The grade Ⅲ leukopenia, thrombocytopenia and anemia rates were 19.5%, 23.0% and 13.8%, respectively. No grade Ⅳ hematologic toxicity occurred. The common non- hematologic toxicities were edema（74.7%）, nausea（48.3%）, bone pain（42.5%）, rash（36.8%）, diarrhea（34.5%）, fever（23.0%）, cramp（11.5%）and impaired liver function （3.4%）. No patient experienced grade Ⅳ non- hematologic toxicity. No adverse effects related death occurred.</p><p><b>CONCLUSION</b>Our results revealed the excellent early haematology, cytogenetic and molecular responses and safety of Xinwei in treating patients with CML-CP.</p>
Assuntos
Humanos , Anemia , Protocolos de Quimioterapia Combinada Antineoplásica , Citogenética , Medicamentos Genéricos , Mesilato de Imatinib , Leucemia Mielogênica Crônica BCR-ABL Positiva , Estudos Prospectivos , Inibidores de Proteínas Quinases , Indução de Remissão , Trombocitopenia , Resultado do TratamentoRESUMO
The 13th International Conference on Malignant Lymphoma (ICMC) was held in Lugano, Switzerland from June 17 to 20, 2015.There was the enormous progress in the treatment of chronic lymphocytic leukemia in the past years, especially in 2014, 4 new agents for the treatment of chronic lymphocytic leukemia were approved in USA and Europe, which caused great attention on the issue of chronic lymphocytic leukemia.The latest progress of chronic lymphocytic leukemia reported at the conference was briefly introduced in this paper.